Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis - Focus on subcutaneous tocilizumab

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 913-919

  Nakashima, Yasuharu ^a   Kondo, Masakazu ^b   Miyahara, Hisaaki ^c   Iwamoto, Yukihide ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Kondo Clinic of Rheumatology and Orthopaedic Surgery   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

Review; Rheumatoid arthritis; Subcutaneous injection; Tocilizumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; LIVER ENZYME; TOCILIZUMAB; TRIACYLGLYCEROL; MONOCLONAL ANTIBODY;

AREA UNDER THE CURVE; BACTERIAL ARTHRITIS; CELLULITIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GASTROENTERITIS; HEMATOLOGICAL PARAMETERS; HUMAN; INFECTION; INJECTION SITE REACTION; MANAGED CARE; MAXIMUM PLASMA CONCENTRATION; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARMACODYNAMICS; PNEUMONIA; REVIEW; RHEUMATOID ARTHRITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ARTHRITIS, RHEUMATOID; DRUG DELIVERY SYSTEM; MEDICATION COMPLIANCE; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; DRUG DELIVERY SYSTEMS; HUMANS; INJECTIONS, SUBCUTANEOUS; MEDICATION ADHERENCE; PATIENT SATISFACTION;

EID: 84904035777     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S52099     Document Type: Review

References (37)

1. Boissier MC, Semerano L, Challal S, Saidenberg-Kermanac'h N, Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun. 2012;39(3):222-228.
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. 2002 Update. Arthritis Rheum. 2002;46(2):328-346.
3. Müller N, Döring F, Klapper M, et al. Interleukin-6 and Tumour Necrosis Factor-α differentially regulate lincRNA transcripts in cells of the innate immune system in vivo in human subjects with rheumatoid arthritis. Cytokine. 2014;68(1):65-68.
4. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163-196.
5. Alghasham A, Rasheed Z. Therapeutic targets for rheumatoid arthritis: Progress and promises. Autoimmunity. 2014;47(2):77-94.
6. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying anti-rheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69(6):976-986.
7. Smolen JS, Aletaha D, Bijlsma J W, et al; T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-637.
8. Schipper LG, Vermeer M, Kuper HH, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis. 2012;71(6):845-850.
9. Wang J, Platt A, Upmanyu R, et al. IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open. 2013;3(8):e003199.
10. Nishimoto N. Interleukin-6 as a therapeutic target in candidate infam-matory diseases. Clin Pharmacol Ther. 2010;87(4):483-487.
11. Smolen JS, Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants. Arthritis Rheum. 2011;63(1):43-52.
12. Brandão FM, Coelho P, Pinto P, Combe B. Tocilizumab - a new step in rheumatoid arthritis treatment. Acta Reumatol Port. 2010;35(3): 302-312.
13. Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis. 2013;72(4): 583-589.
14. Smolen JS, Schoels MM, Nishimoto N, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2013;72(4):482-492.
15. Oldfeld V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs. 2009;69(5):609-632.
16. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): signifcant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12-19.
17. Smolen JS, Beaulieu A, Rubbert-Roth A, et al; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987-997.
18. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab mono-therapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96.
19. Emery P, Keystone E, Tony H P, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516-1523.
20. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011;63(3):609-621.
21. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968-2980.
22. Yazici Y, Curtis JR, Ince A, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012;71(2):198-205.
23. Maini RN, Taylor PC, Szechinski J, et al; CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817-2829.
24. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72(1):43-50.
25. Gabay C, Emery P, van Vollenhoven R, et al; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541-1550.
26. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic beneft from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162-1167.
27. Nakashima Y, Kondo M, Fukuda T, et al. Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data. Mod Rheumatol. 2014;24(2):258-264.
28. Nakashima Y, Kondo M, Harada H, et al. Clinical evaluation of tocili-zumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol. 2010;20(4):343-352.
29. Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence. 2009;3:335-344.
30. Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care. 2008;6(1):1-14.
31. Williams EL, Edwards CJ. Patient preferences in choosing anti-TNF therapies-R1. Rheumatolog y (Oxford). 2006;45(12):1575-1576.
32. Zhang X, Georgy A, Rowell L. Pharmacokinetics and pharmacodynam-ics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects. Int J Clin Pharmacol Ther. 2013;51(6):443-455.
33. Zhang X, Chen YC, Fettner S, et al. Pharmacokinetics and phar-macodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2013;51(8):620-630.
34. Ohta S, Tsuru T, Terao K, et al. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). J Clin Pharmacol. 2014;54(1):109-119.
35. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73(1):69-74.
36. Ogata A, Tanimura K, Sugimoto T, et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(3):344-354.
37. Burmester GR, Rubbert-Roth A, Cantagrel AG, et al. A randomized, double-blind, parallel group study of the safety and efficacy of tocilizumab SC versus tocilizumab I V, in combination with traditional Dmards in patients with moderate to severe RA. Arthritis Rheum. 2012;64(10):S1075-S1075.